Despite its profound impact on patient health, anemia of chronic kidney disease (CKD) remains underdiagnosed and undertreated.

Erythropoietin (Epo) exhibits properties that may attenuate this process and enhance neovascularization, thereby preserving jeopardized myocardium. Potentially adverse effects of Epo, ...

Stanford University scientists have found that erythropoietin (EPO), a protein identified nearly 40 years ago for its ability to stimulate the production of red blood cells also plays a surprising ...

Erythropoietin (EPO), a glycoprotein hormone, is a fundamental regulator of erythropoiesis. The expression of EPO is tightly regulated by local changes in the partial pressure of oxygen.

Erythropoietin, aka EPO, is best known for its role in the Lance Armstrong cheating scandal. But EPO is also the star of another, darker tale.

The global erythropoietin drugs market was valued at approximately USD 6.87 billion in 2022 and is projected to grow at a healthy growth rate of around 1.5% during the forecast period from 2023 to ...

First market approval for Genexine discovered and developed therapeutic drug, Efesa (Efepoetin alfa), a long-acting erythropoietin (EPO) for the treatment of Chronic Kidney disease Induced anemia ...

The Erythropoietin (EPO) drugs market is a vital segment of the pharmaceutical industry that focuses on the development and distribution of medications aimed at stimulating red blood cell production.

Low plasma erythropoietin (EPO) levels are a major factor in anemia of prematurity. Erythroid progenitors from neonates have responded well to EPO in vitro, (studies performed outside a living ...

Erythropoietin (EPO) is a 30.4 kDa glycoprotein comprised of one 165 amino acid residues chain with four glycosylation locations (Figure 1). The hormone is produced naturally in the kidneys ...

Donating blood is one of the most important and life-saving things everyday people can do. Yet, while it’s often seen as ...